Compare LQDA & RYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | RYN |
|---|---|---|
| Founded | 2004 | 1926 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.4B |
| IPO Year | 2020 | 1994 |
| Metric | LQDA | RYN |
|---|---|---|
| Price | $68.52 | $20.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $41.00 | $26.00 |
| AVG Volume (30 Days) | 1.5M | ★ 3.2M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 11.73% |
| EPS Growth | ★ 51.81 | 26.78 |
| EPS | ★ 1.26 | N/A |
| Revenue | $158,320,000.00 | ★ $484,485,000.00 |
| Revenue This Year | $278.87 | $214.97 |
| Revenue Next Year | $57.13 | $10.35 |
| P/E Ratio | $54.56 | ★ N/A |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $21.15 | $19.49 |
| 52 Week High | $93.61 | $27.06 |
| Indicator | LQDA | RYN |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 39.23 |
| Support Level | $30.48 | $19.53 |
| Resistance Level | $92.35 | $21.90 |
| Average True Range (ATR) | 3.20 | 0.48 |
| MACD | -0.54 | -0.10 |
| Stochastic Oscillator | 22.32 | 10.60 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Rayonier Inc is a timberland real estate investment trust engaged in the ownership, management, and investment of timberlands. The company operates through Southern Timber, Pacific Northwest Timber, and Real Estate segments. The Southern Timber and Pacific Northwest Timber segments are involved in harvesting timber and related activities, as well as value-added services such as licensing properties for hunting, leasing land for mineral extraction and communication infrastructure, land-based solutions including carbon capture and solar energy, and log trading. The Real Estate segment is engaged in land sales across various categories, as well as residential and commercial leasing activities. It generates the majority of its revenue from the Southern Timber segment.